RAPPEL : Stella-Jones tiendra une téléconférence pour discuter des résultats du troisième trimestre
November 06, 2023 07:00 ET
|
Stella-Jones Inc
MONTRÉAL, 06 nov. 2023 (GLOBE NEWSWIRE) -- Stella-Jones Inc. (TSX:SJ). OUVERTE AUX :Investisseurs, analystes et autres personnes intéressées DATE :Mardi le 7 novembre 2023 HEURE :10 h 00...
BioNTech veröffentlicht Ergebnisse des dritten Quartals 2023 und Informationen zur Geschäftsentwicklung
November 06, 2023 06:45 ET
|
BioNTech SE
Positive klinische Daten-Updates für Produktkandidaten aus verschiedenen Wirkstoffklassen, darunter die Antikörper-Wirkstoff-Konjugat („ADC“)-Kandidaten BNT323/DB-1303 und BNT325/DB-1305, der...
BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update
November 06, 2023 06:45 ET
|
BioNTech SE
Positive clinical data updates across multiple drug classes including antibody-drug conjugate (ADC) candidates BNT323/DB-1303, BNT325/DB-1305, CAR-T candidate BNT211, T cell therapy candidate BNT221...
Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update
November 03, 2023 07:30 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today reported financial results for the quarter ended September 30, 2023, and provided a business update.
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
November 03, 2023 07:00 ET
|
AC Immune SA
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update Results from amyloid plaque reduction analysis (Abeta-PET) after 6 months of treatment with ACI-24.060 in ABATE...
Magna Announces Third Quarter 2023 Results
November 03, 2023 05:00 ET
|
Magna International Inc.
Sales increased 15% to $10.7 billion, compared to a global light vehicle production increase of 4%Diluted earnings per share were $1.37Adjusted diluted earnings per share increased 33% to $1.46Raised...
Kura Oncology Reports Third Quarter 2023 Financial Results
November 02, 2023 16:01 ET
|
Kura Oncology, Inc.
– Completion of enrollment in KOMET-001 registration-directed trial of ziftomenib in NPM1-mutant AML expected by mid-2024 – – Preliminary data from 20 patients in KOMET-007 combination trial of...
NEXGEL to Report Third Quarter 2023 Financial Results on November 13th
November 02, 2023 09:00 ET
|
NEXGEL, INC.
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading...
ProPhase Labs to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 9, 2023 at 11:00 a.m. Eastern Time
November 02, 2023 08:00 ET
|
ProPhase Labs, Inc.
GARDEN CITY, NY, Nov. 02, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics, therapeutics and diagnostics company, will hold a conference call on...
ANOTHER RECORD QUARTER SUSTAINING UPWARD REVISED YEAR-END OUTLOOK
November 02, 2023 07:40 ET
|
Ferrari N.V.
Net revenues of Euro 1,544 million, up 23.5% versus prior year, with total shipments of 3,459 units up 8.5% versus Q3 2022Adjusted EBIT(1) of Euro 423 million, up 41.6% versus prior year, with...